



# Cognitive Performance Concomitant With Vision Acuity Predicts 13-Year Risk for Mortality

Huan Liao<sup>1,2†</sup>, Zhuoting Zhu<sup>3\*†</sup>, Hongxuan Wang<sup>1,2</sup>, Xiaoming Rong<sup>1,2</sup>, Charlotte Aimee Young<sup>4</sup> and Ying Peng<sup>1,2\*</sup>

<sup>1</sup> Department of Neurology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, <sup>2</sup> Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, <sup>3</sup> State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China, <sup>4</sup> Department of Ophthalmology, University of California, San Francisco, San Francisco, CA, United States

**Objective:** To assess the joint impact of cognitive performance and visual acuity on mortality over 13-year follow-up in a representative US sample.

**Methods:** Data from National Health and Nutrition Examination Survey (NHANES) participants ( $\geq 18$  years old) were linked with the death record data of the National Death Index (NDI) with mortality follow-up through December 31, 2011. Cognitive performance was evaluated by the Digit Symbol Substitution Test (DSST) and cognitive performance impairment was defined as the DSST score equal to or less than the median value in the study population. Visual impairment (VI) was defined as presenting visual acuity worse than 20/40 in the better-seeing eye. Risks of all-cause and specific-cause mortality were estimated with Cox proportional hazards models after adjusting for confounders.

**Results:** A total of 2,550 participants 60 years and older from two waves of (NHANES, 1999–2000, 2001–2002) were included in the current analysis. Over a median follow-up period of 9.92 years, 952 (35.2%) died of all causes, of whom 239 (23.1%), 224 (24.0%), and 489 (52.9%) died from cardiovascular disease (CVD), cancer, and non-CVD/non-cancer mortality, respectively. Cognitive performance impairment and VI increased the odds for mortality. Co-presence of VI among cognitive impaired elderly persons predicted nearly a threefold increased risk of all-cause mortality [hazard ratios (HRs), 2.74; 95% confidence interval (CI), 2.02–3.70;  $P < 0.001$ ] and almost a fourfold higher risk of non-CVD/non-cancer mortality (HR, 3.72; 95% CI, 2.30–6.00;  $P < 0.001$ ) compared to having neither impairment.

**Conclusion:** People aged 60 years and over with poorer cognitive performance were at higher risk of long-term mortality, and were especially vulnerable to further mortality when concomitant with VI. It is informative for clinical implication in terms of early preventive interventions.

**Keywords:** cognitive performance, vision acuity, joint impact, mortality, NHANES

**Abbreviations:** BMI, body mass index; CIs, confidence intervals; CRP, C-reactive protein; CVD, cardiovascular disease; DSST, Digit Symbol Substitution Test; HRs, hazard ratios; ICD, International Classification of Diseases; NDI, National Death Index; NHANES, National Health and Nutrition Examination Survey; PIR, poverty income ratio; SE, standard errors; VI, visual impairment.

## OPEN ACCESS

### Edited by:

Patrizia Mecocci,  
University of Perugia, Italy

### Reviewed by:

Yunhwan Lee,  
Ajou University, South Korea  
Bao-Liang Zhong,  
Wuhan Mental Health Center, China

### \*Correspondence:

Zhuoting Zhu  
zhuoting\_zhu@hotmail.com  
Ying Peng  
docpengy123@163.com;  
pengy2@mail.sysu.edu.cn

<sup>†</sup>These authors have contributed  
equally to this work

**Received:** 13 October 2018

**Accepted:** 06 March 2019

**Published:** 22 March 2019

### Citation:

Liao H, Zhu Z, Wang H, Rong X,  
Young CA and Peng Y (2019)  
Cognitive Performance Concomitant  
With Vision Acuity Predicts 13-Year  
Risk for Mortality.  
*Front. Aging Neurosci.* 11:65.  
doi: 10.3389/fnagi.2019.00065

## INTRODUCTION

Life expectancy in industrialized countries has been projected to increase continuously, with most of the projected gains occurring in older ages (Kontis et al., 2017). However, a non-negligible disadvantage to gains in longevity is the increased risk of the impairment of both vision and cognition with age. VI is highly prevalent among aged people, not only leading to morbidity, but imposing an impact on the risk of mortality as well (Zhang et al., 2016; Zhu et al., 2016). It has been estimated that the number of visually impaired people could double by 2050 (Varma et al., 2016). The extended life expectancy and aging population, rising rapidly around the world, have also led to increasing prevalence of dementia (Brookmeyer et al., 2007). Cognitive decline and impairment associated with age have also been proposed to be linked with an increased mortality (Sachs et al., 2011). Hence, well-established identification and management on both visual and cognitive impairment are particularly crucial for improving health in later lives.

Emerging evidence suggests a strong linkage between impairment of vision and cognitive impairment (Rogers and Langa, 2010; Elyashiv et al., 2014; Chen et al., 2017). It has been proposed in large cohort studies that higher rates of cognitive performance impairment exist among aged adults with VI (Elyashiv et al., 2014). In a prospective cohort study, VI has been demonstrated to predict cognitive decline (Lin et al., 2004). Furthermore, several studies have shown improved cognitive performance scores by treating reduced vision via cataract surgery (Tamura et al., 2004; Ishii et al., 2008). Alternatively, severe cognitive performance impairment may raise the risk of incident functional VI, even though the eyes remain structurally healthy (Chen et al., 2017). Although VI and cognitive performance impairment have been associated with mortality separately as mentioned above, much less is known about the joint effects of cognitive impairment and VI on mortality. It has been reported that concomitant VI and cognitive impairment increases mortality in a US study (Liu et al., 2016), while no relation was found in a Japanese study (Mitoku et al., 2016). Notably, in those two studies, VI was assessed by self-reporting and the generalizability of the studies are limited. Furthermore, those two studies did not explore the specific mortality associated with the joint effect of visual and cognitive impairment.

The NHANES is a continuous population-based study, which provides an opportunity to investigate the impact of cognitive performance concomitant with VI on mortality in a nationally representative population of the non-institutionalized US civilian. We hypothesize that not only does cognitive performance impairment and VI independently predicts mortality, but the combination of both also predicts increase mortality.

## MATERIALS AND METHODS

### Sample and Population

This dataset was extracted from two cycles of NHANES (1999–2000, 2001–2002), which is an ongoing study conducted

every 2 years by Centers for Disease Control and Prevention and National Center for Health Statistics (2005). Participants were recruited from the US non-institutionalized civilian population using stratified multistage design, with oversampling of certain subgroups<sup>1</sup>. Participants were invited to a mobile examination center for an extensive examination that included physical examinations, laboratory tests, and questionnaires. All participants were informed about the study and gave their written consent prior to assessments. The study protocols and data collection were conducted according to ethical standards. The research adhered to the guidelines of the Declaration of Helsinki.

### Assessment of Cognitive Performance

The DSST was included in the 1999–2002 cycles of NHANES to assess cognitive performance among participants aged 60 years and older. The DSST is a widely used test with high sensitivity for assessing sustained attention, psychomotor speed, and working memory in epidemiologic and neuropsychologic studies (Wechsler, 2007). Based on codes, participants were required to pair the numbers (1–9) with corresponding symbols. The total number of correctly matched symbols within 2 min was calculated for the DSST points (0–133). Higher correct scores represent better cognitive performance. Since there is no gold standard cutoff for cognitive performance impairment based on the DSST score, we defined cognitive performance impairment as below the median DSST score (DSST value of 40), consistent with methods previously described in other studies (Loprinzi et al., 2017).

### Assessment of Visual Acuity

Presenting visual acuity was evaluated for each eye with participants' usual distance vision correction with an autorefractor (ARK-760, Nidek Co., Ltd.). Details of methods for visual acuity measurement have been described elsewhere (Ko et al., 2012). Presenting visual acuity worse than 20/40 in the better-seeing eye was used to define VI based on the latest guidelines of the US Preventive Services Task Force (Chou et al., 2016).

### Mortality Data

Mortality data were obtained from the NDI through a probabilistic matching algorithm (Loprinzi and Addoh, 2016). Mortality for NHANES participants ( $\geq 18$  years old) was followed-up through December 31, 2011. Participants were considered alive when they could not be matched with NDI data. The specific cause of death was coded according to the tenth revision of ICD, Injuries and Causes of death (ICD-10). ICD-10 codes I00–I09, I11, I13, and I20–I51 were used to define the death from heart disease, and codes I60–I69 indicated to the decease from cerebrovascular diseases. The combination codes of deaths from heart disease and cerebrovascular diseases were used to represent deaths from CVD. ICD-10 codes C00–C97 were used to define cancer mortality. Those who were not classified as CVD or cancer-related deaths were considered as death due to non-CVD/non-cancer cause. The follow-up period for each

<sup>1</sup><http://www.cdc.gov/nchs/nhanes.htm>

participant was calculated as the time length from the date of the interview to either the date of death or at the end of the follow-up (December 31, 2011), whichever happened first.

## Covariates

Covariates were selected on the basis of established association in previous studies both with exposure (VI or cognitive performance) and outcome (mortality) (Chen et al., 2017). All sociodemographic factors (age, gender, race, education level, marital status, and PIR), health-related behaviors (smoking status and alcohol consumption), and comorbid medical conditions (BMI, diabetes, hypertension, high cholesterol, CRP level, history of CVD, and cancer) were assessed using self-reported questionnaires or laboratory tests.

Ethnicity was classified as Non-Hispanic White, Non-Hispanic Black, Mexican American, and other. Education level was classified as less than high school degree and equal to or more than high school diploma. Marital status (unmarried and other, married/with a partner) was categorized as a two-level covariate. PIR, the indicator of family income, was categorized as below poverty (<1.00) and at or above poverty ( $\geq 1.00$ ). Smoking status was defined as two groups: never, former/current smoker. Alcohol consumption was classified as lifetime abstainer or former drinker, current drinker with equal to or less than 3, and current drinker with more than three drinks per week.

Body mass index was calculated as weight in kilograms divided by height in meters squared. Participants were defined as having diabetes if they had self-reported physician diagnosis of diabetes, glycosylated hemoglobin (%) levels of 6.5% or more, or used insulin or the prescription of diabetic agents (Varma et al., 2014). The presence of hypertension was defined by self-reported history of hypertension; or the use of antihypertensive agents; or mean systolic blood pressure  $\geq 140$  mm Hg; and/or mean diastolic blood pressure  $\geq 90$  mm Hg after three measurements. Individuals were classified as having high cholesterol with serum total cholesterol  $\geq 240$  mg/dL or the use of lipid-lowering agent. High level of CRP was defined as CRP 1 mg/dL or over. History of CVD was defined by physician diagnosis of congestive heart failure, coronary heart disease, angina, heart attack, or stroke. History of cancer was based on a previous physician's diagnosis of cancer.

## Statistical Analysis

We followed the standard NHANES analytic procedures for weighting, taking the complex, stratified design of NHANES into account. Continuous data were presented as means and SEs, and categorical variables were shown as numbers and weighted percentages. We used the design-adjusted one-way analysis of variance and Rao-Scott Pearson  $\chi^2$  for the comparison of continuous and categorical variables, respectively. Plots of survival curves were generated using Kaplan-Meier estimates and the log-rank test was used for comparing the survival distributions among groups. The risks of mortality associated with cognitive performance impairment or VI were estimated using Cox proportional hazards regression models to estimate HRs with 95% CIs. All models were first adjusted for age, gender, ethnicity, and sociodemographic factors (education level,

marital status, and income status), and then additionally for BMI, smoking status, drinking status, hypertension, diabetes mellitus, cholesterol level, CRP, history of CVD, and cancer. We also evaluated the joint effect of cognitive performance impairment and VI on mortality by adjusting for multiple covariates. To correct the estimates for non-response, inverse probability weighting was used in the sensitivity analyses. Sensitivity analyses were also performed after Markov chain Monte-Carlo imputations to address the missing data. The proportional-hazards assumption for each variable was tested by generating time-dependent covariates, with  $P$ -value < 0.05 for the interaction of the variable and a function of survival time regarded as violating the assumption. All variables were found to be valid ( $P > 0.05$ ). All data analyses were performed using STATA (ver. 14.0; StataCorp., College Station, TX, United States). Two-sided  $P$ -values less than 0.05 were considered to indicate statistical significance.

## RESULTS

A total of 3,234 participants aged 60 years or older participated in NHANES (1999/2002). Among these individuals, 684 were excluded because of missing information on DSST score (522 participants) and missing data on visual acuity (162 participants), leading to a final analytical sample of 2,550 participants. Compared with participants with complete data, participants with incomplete data were older ( $P < 0.001$ ), more likely to be non-Hispanic black ( $P < 0.001$ ) and be unhealthy regarding lifestyle and clinical measures. Other baseline characteristics of subjects excluded and included are shown in **Supplementary Table S1**. Among the 2,550 participants included in the current analysis, the mean (SE) DSST score was  $46.9 \pm 0.60$  points. **Table 1** provides basic characteristics of participants overall and by quartile of DSST score. The mean (SE) age was  $70.6 \pm 0.29$  years, 56.5% of participants were women and 84.0% non-Hispanic white. Participants with a higher quartile of DSST score were more likely to have better vision, be younger, non-Hispanic white people, well educated, married or with partner, higher income index, current drinker, and healthier in terms of diabetes, hypertension, and history of CVD. There was no significant difference in other characteristics within quartile of DSST score. **Supplementary Table S2** illustrates demographic, health-related behaviors, and general health characteristics among participants with and without VI. Older age, non-white ethnicity, lower education level, unmarried status, lower BMI value, hypertension, and history of CVD or cancer were significantly associated with VI.

After a median follow-up period of 9.92 years, 952 (35.2%) deaths occurred. Of 952 deaths, 239 (23.1%), 224 (24.0%), and 489 (52.9%) cases were attributed to CVD, cancer, and non-CVD/non-cancer causes, respectively. The comparisons of quartiles of DSST score, VI, and baseline characteristics by mortality status are shown in **Table 2**. All-cause mortality rates were higher for those participants with a lower quartile of DSST score and those with VI. Age- and gender-adjusted Cox proportional hazards regression models showed covariates,

**TABLE 1** | Baseline characteristics of participants by digit-symbol substitution test score quintile.

Characteristics	Overall (N = 2,550)	DSST score <sup>a</sup>				P <sup>b</sup>
		Q1 (n = 591)	Q2 (n = 630)	Q3 (n = 644)	Q4 (n = 685)	
VI						
No	2,278 (91.6%)	471 (78.3%)	545 (88.3%)	600 (93.9%)	662 (97.3%)	<b>&lt;0.001</b>
Yes	272 (8.4%)	120 (21.7%)	85 (11.7%)	44 (6.1%)	23 (2.7%)	
Age (SE), years	70.6 ± 0.29	74.5 ± 0.64	72.7 ± 0.36	71.0 ± 0.36	67.4 ± 0.26	<b>&lt;0.001</b>
Gender						
Male	1,257 (43.5%)	312 (42.8%)	337 (48.0%)	325 (45.3%)	283 (39.7%)	0.098
Female	1,293 (56.5%)	279 (57.2%)	293 (52.0%)	319 (54.7%)	402 (60.3%)	
Race						
Non-Hispanic white	1,543 (84.0%)	197 (61.0%)	365 (81.1%)	433 (86.6%)	548 (92.9%)	<b>&lt;0.001</b>
Non-Hispanic black	370 (6.5%)	144 (17.6%)	105 (8.0%)	78 (5.1%)	43 (2.2%)	
Mexican American	487 (2.7%)	198 (7.2%)	123 (3.0%)	100 (2.1%)	66 (1.1%)	
Other	150 (6.9%)	52 (14.3%)	37 (7.8%)	33 (6.2%)	28 (3.8%)	
Education						
Less than high school	1,000 (29.0%)	448 (67.0%)	302 (43.0%)	170 (21.9%)	80 (10.5%)	<b>&lt;0.001</b>
High school and over	1,549 (71.0%)	142 (33.0%)	328 (57.0%)	474 (78.1%)	605 (89.5%)	
Marital status						
Unmarried and other	911 (35.4%)	248 (49.7%)	259 (43.7%)	227 (35.2%)	177 (24.9%)	<b>&lt;0.001</b>
Married/with a partner	1,523 (64.6%)	305 (50.3%)	344 (56.3%)	387 (64.8%)	487 (75.1%)	
PIR						
Below poverty (<1)	340 (12.1%)	175 (36.2%)	85 (12.9%)	58 (9.5%)	22 (3.8%)	<b>&lt;0.001</b>
At or above poverty (≥1)	1,926 (87.9%)	341 (63.8%)	492 (87.2%)	521 (90.5%)	572 (96.2%)	
Smoking status						
Never	1,190 (47.0%)	294 (54.1%)	288 (45.5%)	291 (46.3%)	317 (45.6%)	0.091
Former/current	1,355 (53.0%)	296 (45.9%)	341 (54.5%)	352 (53.7%)	366 (54.4%)	
Alcohol consumption						
Lifetime abstainer/former drinker	803 (32.7%)	232 (44.9%)	220 (38.8%)	188 (32.1%)	163 (24.5%)	<b>&lt;0.001</b>
Current drinker (≤3 drinks/w)	1,253 (48.9%)	285 (46.7%)	306 (47.4%)	316 (50.7%)	346 (49.3%)	
Current drinker (>3 drinks/w)	434 (18.5%)	55 (8.5%)	89 (13.8%)	123 (17.3%)	167 (26.2%)	
BMI (SE), kg/m <sup>2</sup>	28.2 ± 0.14	27.9 ± 0.40	27.9 ± 0.24	28.4 ± 0.25	28.4 ± 0.21	0.412
Diabetes mellitus						
No	1,955 (82.4%)	398 (73.3%)	462 (77.5%)	513 (83.2%)	582 (88.3%)	<b>&lt;0.001</b>
Yes	526 (17.6%)	172 (26.7%)	150 (22.5%)	110 (16.8%)	94 (11.7%)	
Hypertension						
No	833 (34.2%)	167 (26.8%)	189 (30.7%)	209 (31.8%)	268 (41.1%)	<b>&lt;0.001</b>
Yes	1,659 (65.8%)	403 (73.2%)	428 (69.3%)	421 (68.2%)	407 (58.9%)	
High cholesterol						
No	1,463 (57.6%)	353 (60.9%)	361 (56.7%)	364 (56.5%)	385 (57.5%)	0.656
Yes	978 (42.4%)	199 (39.1%)	246 (43.3%)	253 (43.5%)	280 (42.5%)	
High CRP						
No	2,141 (88.0%)	469 (83.2%)	538 (88.0%)	545 (88.6%)	589 (89.5%)	0.093
Yes	286 (12.0%)	81 (16.8%)	65 (12.0%)	67 (11.4%)	73 (10.5%)	
History of CVD						
No	1,973 (77.1%)	431 (68.4%)	445 (67.0%)	511 (79.3%)	586 (85.0%)	<b>&lt;0.001</b>
Yes	577 (22.9%)	160 (31.6%)	185 (33.0%)	133 (20.7%)	99 (15.0%)	
History of cancer						
No	2,068 (78.7%)	510 (80.5%)	500 (77.6%)	513 (78.7%)	545 (78.6%)	0.779
Yes	482 (21.3%)	81 (19.5%)	130 (22.4%)	131 (21.3%)	140 (21.4%)	

DSST, Digit-Symbol Substitution Test; VI, visual impairment; SE, standard error; BMI, body mass index. Boldface indicates statistical significance. All proportions, means, and SE are weighted estimates of the US population characteristics, taking into account the complex sampling design of the NHANES. <sup>a</sup>Q1–Q4, first quartile–fourth quartile. <sup>b</sup>All P-values were calculated using one-way analysis of variance for continuous variables and the design-adjusted Rao–Scott Pearson  $\chi^2$  test for categorical variables.

**TABLE 2** | All-cause mortality by baseline characteristics.

Characteristics	Number of	Number of	Unadjusted	HR (95% CI) <sup>a</sup>
	survived subjects, n = 1,598 (%)	died subjects, n = 952 (%)		
<b>DSST score</b>				
Quartile 4	546 (45.4%)	139 (19.3%)	<0.001	Reference
Quartile 3	425 (28.3%)	219 (24.8%)		<b>1.37 (1.11–1.69)</b>
Quartile 2	328 (16.4%)	302 (33.1%)		<b>2.37 (1.93–2.93)</b>
Quartile 1	299 (10.0%)	292 (22.8%)		<b>2.37 (1.91–2.94)</b>
<b>VI</b>				
No	1,475 (94.3%)	803 (86.8%)	<0.001	Reference
Yes	123 (5.7%)	149 (13.2%)		<b>1.43 (1.18–1.73)</b>
Age (SE), years	68.4 ± 0.23	74.7 ± 0.32	<0.001	<b>1.11 (1.10–1.12)</b>
<b>Gender</b>				
Male	729 (41.2%)	528 (47.7%)	0.025	Reference
Female	869 (58.8%)	424 (52.3%)		<b>0.66 (0.56–0.79)</b>
<b>Race</b>				
Non-Hispanic white	885 (82.2%)	658 (87.2%)	0.007	Reference
Non-Hispanic black	238 (6.6%)	132 (6.3%)		1.22 (0.98–1.52)
Mexican American	361 (3.1%)	126 (1.9%)		0.83 (0.67–1.03)
Other	114 (8.1%)	36 (4.6%)		0.70 (0.48–1.02)
<b>Education</b>				
Less than high school	601 (25.7%)	399 (35.1%)	<0.001	Reference
High school and over	997 (74.3%)	552 (64.9%)		<b>0.77 (0.66–0.89)</b>
<b>Marital status</b>				
Unmarried and other	507 (30.4%)	404 (44.7%)	<0.001	Reference
Married/with a partner	1,025 (69.6%)	498 (55.3%)		<b>0.71 (0.59–0.85)</b>
<b>PIR</b>				
Below poverty (<1)	192 (9.6%)	148 (16.4%)	0.021	Reference
At or above poverty (≥1)	1,216 (90.4%)	710 (83.6%)		<b>0.67 (0.49–0.93)</b>
<b>Smoking status</b>				
Never	787 (50.2%)	403 (41.0%)	<0.001	Reference
Former/current	807 (49.8%)	548 (59.0%)		<b>1.58 (1.36–1.83)</b>
<b>Alcohol consumption</b>				
Lifetime abstainer/former drinker	503 (32.4%)	300 (33.2%)	0.130	Reference
Current drinker (≤3 drinks/w)	771 (47.8%)	482 (50.9%)		1.11 (0.91–1.35)
Current drinker (>3 drinks/w)	283 (19.9%)	151 (16.0%)		0.89 (0.70–1.13)
BMI (SE), kg/m <sup>2</sup>	28.6 ± 0.16	27.5 ± 0.20	<0.001	1.00 (0.99–1.01)
<b>Diabetes mellitus</b>				
No	1,247 (84.1%)	708 (79.2%)	0.015	Reference
Yes	316 (15.9%)	210 (20.8%)		<b>1.39 (1.15–1.69)</b>
<b>Hypertension</b>				
No	569 (37.6%)	264 (28.0%)	<0.001	Reference
Yes	992 (62.4%)	667 (72.0%)		1.16 (0.96–1.41)
<b>High cholesterol</b>				
No	900 (55.5%)	563 (61.3%)	0.022	Reference
Yes	638 (44.5%)	340 (38.7%)		<b>0.86 (0.75–1.00)</b>
<b>High CRP</b>				
No	1,370 (89.5%)	771 (85.4%)	0.003	Reference
Yes	161 (10.5%)	125 (14.6%)		<b>1.54 (1.33–1.79)</b>
<b>History of CVD</b>				
No	1,333 (83.0%)	640 (66.1%)	<0.001	Reference
Yes	265 (17.0%)	312 (33.9%)		<b>1.61 (1.33–1.96)</b>
<b>History of cancer</b>				
No	1,361 (82.2%)	707 (72.3%)	<0.001	Reference
Yes	237 (17.8%)	245 (27.7%)		<b>1.30 (1.08–1.57)</b>

DSST, Digit-Symbol Substitution Test; VI, visual impairment; SE, standard error; BMI, body mass index; CI, confidence interval; HR, hazard ratio. Boldface indicates statistical significance. All-cause mortality was assessed through December 31, 2011. All proportions, means, and SEs are weighted estimates of the US population characteristics, taking into account the complex sampling design of the NHANES. Unadjusted P-values were calculated using one-way analysis of variance for continuous variables and the design-adjusted Rao-Scott Pearson  $\chi^2$  test for categorical variables. <sup>a</sup>Adjusted for age and gender.


**TABLE 3** | Cox proportional hazards models for all-cause and specific-cause mortality by Digit-Symbol Substitution Test score or VI status.

Status	Model 1 <sup>a</sup>	Model 2 <sup>b</sup>
	(HR and 95% CI)	(HR and 95% CI)
<b>Cognitive impairment, Present vs. Absent<sup>c</sup></b>		
All-cause mortality	<b>2.00 (1.65–2.42)</b>	<b>1.99 (1.60–2.47)</b>
Cardiovascular mortality	<b>1.90 (1.39–2.59)</b>	<b>1.72 (1.18–2.51)</b>
Cancer mortality	1.21 (0.76–1.90)	1.38 (0.78–2.45)
Non-cancer/non-cardiovascular mortality	<b>2.57 (1.90–3.47)</b>	<b>2.44 (1.70–3.49)</b>
<b>VI, Present vs. Absent<sup>c</sup></b>		
All-cause mortality	<b>1.37 (1.07–1.73)</b>	<b>1.51 (1.16–1.96)</b>
Cardiovascular mortality	1.36 (0.87–2.11)	1.43 (0.80–2.56)
Cancer mortality	0.86 (0.46–1.61)	0.97 (0.46–2.01)
Non-cancer/non-cardiovascular mortality	<b>1.57 (1.09–2.24)</b>	<b>1.75 (1.22–2.52)</b>

HR, hazard ratio; CI, confidence interval; DSST, Digit-Symbol Substitution Test; VI, visual impairment. Boldface indicates statistical significance. All-cause mortality was assessed through December 31, 2011. <sup>a</sup>Model 1: Adjusted for age, gender, race, education level, marital status, income status. <sup>b</sup>Model 2: Model 1 plus additional adjustments for BMI, smoking status, drinking status, diabetes mellitus, hypertension, cholesterol level, CRP, history of CVD, and cancer. <sup>c</sup>Cognitive impairment defined as DSST score ≤ 40 (median score in population); VI defined as presenting visual acuity worse than 20/40.

including age, gender, education level, marital status, family income index, smoking status, diabetes, cholesterol level, CRP level, history of CVD, and cancer, were significantly associated with risks of mortality. After adjusting for multiple variables, the Cox models indicated that poorer survival from all-cause, CVD, and non-CVD/non-cancer was associated with cognitive performance impairment (all cause HR, 1.99; 95% CI, 1.60–2.47; CVD HR, 1.72; 95% CI, 1.18–2.51; and non-CVD/non-cancer HR, 2.44; 95% CI, 1.70–3.49) (Table 3). Similarly, VI predicted increased risk of mortality due to all-cause and non-CVD/non-cancer causes in the multifactorial Cox models (all cause HR, 1.51; 95% CI, 1.16–1.96; and non-CVD/non-cancer HR, 1.75; 95% CI, 1.22–2.52).

Kaplan-Meier curves for all-cause and specific-cause mortality by cognitive performance impairment and concomitant VI are shown in Figure 1. Interactions between cognitive performance impairment and VI were assessed, and no significant interaction was found. Table 4 summarizes the stratified analysis regarding the dual impact of cognitive performance impairment with VI on mortality. Considering participants with neither cognitive performance impairment nor VI as the reference group, risk of mortality was increased among those with cognitive performance impairment but without VI (all-cause HR, 1.92; 95% CI, 1.50–2.47; CVD HR, 1.87; 95% CI, 1.22–2.86; cancer HR, 1.28; 95% CI, 0.71–2.30; and non-CVD/non-cancer HR, 2.31; 95% CI, 1.57–3.39). However, participants with only VI did not show higher risk of mortality. Co-presence of VI among cognitively impaired elderly people further increased nearly threefold risk of all-cause mortality (HR, 2.74; 95% CI, 2.02–3.70) and almost fourfold risk of non-CVD/non-cancer mortality (HR, 3.72; 95% CI, 2.30–6.00). We observed similar results to those reported in the main analyses



in sensitivity analyses using inverse probability weighting for non-response issue (Supplementary Tables S3, S4). After imputations of missing values, we also obtained similar results (Supplementary Tables S5, S6).

## DISCUSSION

In a pooled analysis of two nationally representative samples (2,550 US subjects aged 60 years and over), we observed that both cognitive performance impairment and VI independently predicted poorer survival. Additionally, the co-presence of VI among cognitive impaired elderly predicted higher risk of all-cause mortality and of non-CVD/non-cancer mortality compared to having neither impairment.

Visual impairment as a risk factor for cognitive performance (Lin et al., 2004; Fischer et al., 2016; Chen et al., 2017) in the literature was consistent with our result. In addition, the finding that impaired cognitive performance was a significant predictor of mortality was consistent with previous studies (Dewey and Saz, 2001; Perna et al., 2015; Batty et al., 2016; Lee et al., 2018). Moreover, a recent systematic literature review also supports our results (Dewey and Saz, 2001). In terms of VI, our results and those from previous studies suggested that VI increased the risk of all-cause mortality (McCarty et al., 2001;

Wang et al., 2001; Khanna et al., 2013; Ng et al., 2018). In a recent meta-analysis, containing 29 prospective cohort studies with 269,839 participants and 67,061 deaths, VI was found to be significantly associated with an increased risk of mortality in participants older than 65 years (Zhang et al., 2016).

In our study, we highlighted the finding that impaired cognitive performance accompanied by VI additionally increased the risk of mortality in our study, which was in line with a study conducted in United States (Liu et al., 2016). On the contrary, in a Japanese study, the joint effect of visual and cognitive impairment did not increase the risk of mortality compared to those without visual/hearing and cognitive impairment, while a significant increase in risk of mortality was observed among individuals with dual impairment (visual and hearing) and cognitive impairment (Mitoku et al., 2016). Taking into account the inclusion of hearing status, self-reported visual function and ethnicity in the Japan study might explain the different results. Of note, even though we observed the significant association between VI and mortality, the association between VI but no impaired cognitive performance and mortality did not reach statistical significance. This might due to the small number of participants in the VI but no impaired cognitive performance group ( $n = 67$ ), which might reduce the efficiency of statistical analysis and limit the ability of detecting the association.

**TABLE 4 |** Cox proportional hazards regression models of all-cause and specific cause mortality by cognitive and visual status.

	Number of events	Crude mortality rate <sup>a</sup>	Model 1 <sup>b</sup>	Model 2 <sup>c</sup>	P for interaction <sup>d</sup>
<b>All-cause mortality</b>					
Cognitive and visual status <sup>e</sup>					
Neither CI nor VI (n = 1,262)	331	23.9%	1.00 (reference)	1.00 (reference)	0.735
CI only (n = 1,016)	472	51.8%	<b>1.96 (1.58–2.44)</b>	<b>1.92 (1.50–2.47)</b>	
VI only (n = 67)	27	38.7%	1.22 (0.72–2.08)	1.27 (0.77–2.11)	
Both CI and VI (n = 205)	122	63.3%	<b>2.40 (1.83–3.16)</b>	<b>2.74 (2.02–3.70)</b>	
<b>Cardiovascular mortality</b>					
Cognitive and visual status <sup>e</sup>					
Neither CI nor VI (n = 1,262)	77	5.3%	1.00 (reference)	1.00 (reference)	0.073
CI only (n = 1,016)	123	12.7%	<b>2.07 (1.44–2.97)</b>	<b>1.87 (1.22–2.86)</b>	
VI only (n = 67)	8	14.1%	<b>2.35 (1.09–5.05)</b>	2.31 (0.98–5.41)	
Both CI and VI (n = 205)	31	11.6%	<b>1.90 (1.11–3.25)</b>	1.87 (0.90–3.88)	
<b>Cancer mortality</b>					
Cognitive and visual status <sup>e</sup>					
Neither CI nor VI (n = 1,262)	108	8.0%	1.00 (reference)	1.00 (reference)	0.069
CI only (n = 1,016)	90	9.3%	1.14 (0.72–1.81)	1.28 (0.71–2.30)	
VI only (n = 67)	2	2.1%	0.29 (0.06–1.36)	0.17 (0.02–1.37)	
Both CI and VI (n = 205)	24	11.8%	1.26 (0.57–2.80)	1.65 (0.62–4.39)	
<b>Non-cardiovascular mortality</b>					
Cognitive and visual status <sup>e</sup>					
Neither CI nor VI (n = 1,262)	146	10.7%	1.00 (reference)	1.00 (reference)	0.728
CI only (n = 1,016)	259	29.9%	<b>2.48 (1.79–3.44)</b>	<b>2.31 (1.57–3.39)</b>	
VI only (n = 67)	17	22.5%	1.26 (0.54–2.93)	1.36 (0.62–2.98)	
Both CI and VI (n = 205)	67	39.8%	<b>3.39 (2.22–5.17)</b>	<b>3.72 (2.30–6.00)</b>	

CI, cognitive impairment; VI, visual impairment. Boldface indicates statistical significance. Values are number of HR (95% CI). All-cause and specific-cause mortality was assessed through December 31, 2011. <sup>a</sup>All proportions are weighted estimates of the US population characteristics, taking into account the complex sampling design of the NHANES. <sup>b</sup>Model 1: Adjusted for age, gender, race, education level, marital status, and income status. <sup>c</sup>Model 2: Model 1 plus additional adjustments for BMI, smoking status, drinking status, diabetes mellitus, hypertension, cholesterol level, CRP, history of CVD, and cancer. <sup>d</sup>Interaction between CI and VI. <sup>e</sup>CI defined as DSST score  $\leq 40$  (median score in population); VI defined as presenting visual acuity worse than 20/40.

Several possible reasons may account for the joint effect of VI and cognitive performance impairment on mortality. One possible explanation could be that the VI and cognitive impairment contributed additionally to higher possibility of disability (Whitson et al., 2007), which has a close relationship with mortality (Majer et al., 2011). VI not only increases the risks of fractures, falls, and accidents, but also decreases functional independence and ability to perform basic and instrumental activities in daily life (Keller et al., 1999; DiNuzzo et al., 2001), and so these factors could adversely affect mortality. As well, increased risk of falls, accidents, and poor control of underlying diseases due to cognitive impairment could also reduce survival (Dewey and Saz, 2001; Lievre et al., 2008; Muir et al., 2012). Moreover, impaired cognitive performance can predict functional status (Kelman et al., 1994), particularly motor function, which itself is able to affect mortality (McGuire et al., 2006). Another explanation could be underlying vascular diseases. In our analysis, both impaired cognitive performance and VI were associated with hypertension as well as history of CVD, which were significantly related to death. A large number of studies have described a significant relationship between cognitive impairment and CVD (Dregan et al., 2013;

Gottesman et al., 2014). In some cases, cognitive impairment is a marker for serious vascular conditions, such as atherosclerosis, cerebrovascular disease, and diastolic hypertension (Gale et al., 1996). Additionally, vision function has also been shown to be associated with cardiovascular-related conditions or risk factors (Bergman et al., 2004; Klein et al., 2014). The underlying vascular dysfunction related to both cognitive and visual health may enhance mortality rate. Further studies are warranted to explore other possible explanations.

Relevant public health implications emerge according to our findings. This could inform clinicians that VI and cognitive performance impairment are likely to have co-occurrence in the elderly and could potentially increase their risks of deaths. Although these conditions are not life threatening, they are recognized as markers for disability and vulnerability. Therefore, neuropsychological tests, combined with vision function tests, could be utilized to perform early identification to maximize the potential impact of preventive interventions. Furthermore, rehabilitation of VI in elders, especially among cognitively impaired persons, may potentially improve long-term survival.

Our study included strengths such as a large population-based elderly cohort, relatively long follow-up duration, standardized

objective methods for assessing visual acuity and cognitive performance, access to a wide range of demographic characteristics, health indicators, comorbidities, and access to death records. However, several limitations may limit the interpretation of results. First of all, we could not exclude the residual confounding variables, such as family functioning (Yeh and Liu, 2003; Bambara et al., 2009), which may play a role affecting both VI and cognitive performance, although many confounding factors have been adjusted for. In addition, only baseline measurements of vision function and cognitive performance were employed, and no subsequent functional changes in vision and cognitive performance were examined. Future prospective studies are needed to understand the relationship between changes in cognitive or vision status and survival over time. Thirdly, participants included in the present analysis were younger and healthier regarding lifestyle and clinical measures, which might bias the results. Nevertheless, we used inverse probability weighting model to adjust for non-response and observed similar results. The robustness of our conclusions was again verified after multiple imputation for missing data. Last but not least, cognitive function is a multidimensional construct that cannot be comprehensively evaluated with a single test. However, the DSST is generally thought to be more sensitive than many other measures, especially for milder cognitive impairment. Of note, the DSST exercise relies on visual spatial skills. Although we could not completely mitigate the effect of VI on cognitive performance in the present analysis, the trained interviewer in the NHANES provided safeguards to control this potential confounding effect, including asking participants wear reading glasses when necessary, excluding blind participants and those who were unable to complete a practice session due to visual, physical, or cognitive impairments (NHANES, 1999–2000). Further studies exploring joint effects of cognitive function measured by different tests that are less vision-dependent and visual function on mortality are needed to verify the robustness of our results.

## CONCLUSION

In conclusion, subjects aged 60 years and older with poorer cognitive performance are at higher risk of decreased long-term survival, and are especially vulnerable to further mortality when VI is presented. This could inform clinicians that early preventive interventions could be exercised to potentially improve long-term survival.

## REFERENCES

- Bambara, J. K., Wadley, V., Owsley, C., Martin, R. C., Porter, C., and Dreer, L. E. (2009). Family functioning and low vision: a systematic review. *J. Vis. Impair. Blind.* 103, 137–149. doi: 10.1177/0145482X0910300303
- Batty, G. D., Deary, I. J., and Zaninotto, P. (2016). Association of cognitive function with cause-specific mortality in middle and older age: follow-up of participants in the english longitudinal study of ageing. *Am. J. Epidemiol.* 183, 183–190. doi: 10.1093/aje/kwv139
- Bergman, B., Nilsson-Ehle, H., and Sjostrand, J. (2004). Ocular changes, risk markers for eye disorders and effects of cataract surgery in elderly people: a study

## DATA AVAILABILITY

Data analyzed in current study was from NHANES <http://www.cdc.gov/nchs/nhanes.htm/>.

## ETHICS STATEMENT

This study was carried out in accordance with the recommendations of the National Center for Health Statistics research ethics review board with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the National Center for Health Statistics research ethics review board.

## AUTHOR CONTRIBUTIONS

HL, ZZ, and YP study concept and design. HL and ZZ acquisition of data and drafting of the manuscript. HL, ZZ, and XR analysis and interpretation of data. HL, ZZ, HW, XR, CY and YP critical revision of the manuscript for important intellectual content and final approval of the version to be published.

## FUNDING

This study was supported by National Natural Science Foundation of China (Grant No. 81572481) to YP, the Key Project of Product, Study and Research of Guangzhou city (Grant No. 201508020058) to YP, International Collaboration Program of Universities in Guangdong Province (Grant No. 2012gjh001) to YP, National Natural Science Foundation of China (Grant No. 81502167) to XR, the Fund of Guangdong Science and Technology (No. 2014A020212090) and National Natural Science Foundation of China (No. 81601042) to HW.

## SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fnagi.2019.00065/full#supplementary-material>

- of an urban Swedish population followed from 70 to 97 years of age. *Acta Ophthalmol. Scand.* 82, 166–174. doi: 10.1111/j.1600-0420.2004.00182.x
- Brookmeyer, R., Johnson, E., Ziegler-Graham, K., and Arrighi, H. M. (2007). Forecasting the global burden of Alzheimer's disease. *Alzheimers Dement* 3, 186–191. doi: 10.1016/j.jalz.2007.04.381
- Centers for Disease Control and Prevention and National Center for Health Statistics (2005). *National Health and Nutrition Examination Survey Data*. Hyattsville, MD: US Department of Health and Human Services.
- Chen, S. P., Bhattacharya, J., and Pershing, S. (2017). Association of vision loss with cognition in older adults. *JAMA Ophthalmol.* 135, 963–970. doi: 10.1001/jamaophthalmol.2017.2838



- Chou, R., Dana, T., Bougatso, C., Grusing, S., and Blazina, I. (2016). Screening for impaired visual acuity in older adults: updated evidence report and systematic review for the US preventive services task force. *JAMA* 315, 915–933. doi: 10.1001/jama.2016.0783
- Dewey, M. E., and Saz, P. (2001). Dementia, cognitive impairment and mortality in persons aged 65 and over living in the community: a systematic review of the literature. *Int. J. Geriatr. Psychiatry* 16, 751–761. doi: 10.1002/gps.397
- DiNuzzo, A. R., Black, S. A., Lichtenstein, M. J., and Markides, K. S. (2001). Prevalence [correction of prevalence] of functional blindness, visual impairment, and related functional deficits among elderly Mexican Americans. *J. Gerontol. A Biol. Sci. Med. Sci.* 56, M548–M551. doi: 10.1093/gerona/56.9.M548
- Dregan, A., Stewart, R., and Gulliford, M. C. (2013). Cardiovascular risk factors and cognitive decline in adults aged 50 and over: a population-based cohort study. *Age Ageing* 42, 338–345. doi: 10.1093/ageing/afs166
- Elyashiv, S. M., Shabtai, E. L., and Belkin, M. (2014). Correlation between visual acuity and cognitive functions. *Br. J. Ophthalmol.* 98, 129–132. doi: 10.1136/bjophthalmol-2013-304149
- Fischer, M. E., Cruickshanks, K. J., Schubert, C. R., Pinto, A. A., Carlsson, C. M., Klein, B. E., et al. (2016). Age-related sensory impairments and risk of cognitive impairment. *J. Am. Geriatr. Soc.* 64, 1981–1987. doi: 10.1111/jgs.14308
- Gale, C. R., Martyn, C. N., and Cooper, C. (1996). Cognitive impairment and mortality in a cohort of elderly people. *BMJ* 312, 608–611. doi: 10.1136/bmj.312.7031.608
- Gottesman, R. F., Schneider, A. L., Albert, M., Alonso, A., Bandeen-Roche, K., Coker, L., et al. (2014). Midlife hypertension and 20-year cognitive change: the atherosclerosis risk in communities neurocognitive study. *JAMA Neurol.* 71, 1218–1227. doi: 10.1001/jamaneuro.2014.1646
- Ishii, K., Kabata, T., and Oshika, T. (2008). The impact of cataract surgery on cognitive impairment and depressive mental status in elderly patients. *Am. J. Ophthalmol.* 146, 404–409. doi: 10.1016/j.ajo.2008.05.014
- Keller, B. K., Morton, J. L., Thomas, V. S., and Potter, J. F. (1999). The effect of visual and hearing impairments on functional status. *J. Am. Geriatr. Soc.* 47, 1319–1325. doi: 10.1111/j.1532-5415.1999.tb07432.x
- Kelman, H. R., Thomas, C., Kennedy, G. J., and Cheng, J. (1994). Cognitive impairment and mortality in older community residents. *Am. J. Public Health* 84, 1255–1260. doi: 10.2105/AJPH.84.8.1255
- Khanna, R. C., Murthy, G. V., Giridhar, P., Krishnaiah, S., Pant, H. B., Palamaner Subash Shantha, G., et al. (2013). Cataract, visual impairment and long-term mortality in a rural cohort in India: the Andhra Pradesh eye disease study. *PLoS One* 8:e78002. doi: 10.1371/journal.pone.0078002
- Klein, R., Lee, K. E., Gangnon, R. E., and Klein, B. E. (2014). Relation of smoking, drinking, and physical activity to changes in vision over a 20-year period: the beaver dam eye study. *Ophthalmology* 121, 1220–1228. doi: 10.1016/j.ophtha.2014.01.003
- Ko, F., Vitale, S., Chou, C. F., Cotch, M. F., Saaddine, J., and Friedman, D. S. (2012). Prevalence of nonrefractive visual impairment in US adults and associated risk factors, 1999–2002 and 2005–2008. *JAMA* 308, 2361–2368. doi: 10.1001/jama.2012.85685
- Kontis, V., Bennett, J. E., Mathers, C. D., Li, G., Foreman, K., and Ezzati, M. (2017). Future life expectancy in 35 industrialised countries: projections with a bayesian model ensemble. *Lancet* 389, 1323–1335. doi: 10.1016/S0140-6736(16)32381-9
- Lee, Y., Kim, J., Chon, D., Lee, K. E., Kim, J. H., Myeong, S., et al. (2018). The effects of frailty and cognitive impairment on 3-year mortality in older adults. *Maturitas* 107, 50–55. doi: 10.1016/j.maturitas.2017.10.006
- Lievere, A., Alley, D., and Crimmins, E. M. (2008). Educational differentials in life expectancy with cognitive impairment among the elderly in the United States. *J. Aging Health* 20, 456–477. doi: 10.1177/0898264308315857
- Lin, M. Y., Gutierrez, P. R., Stone, K. L., Yaffe, K., Ensrud, K. E., Fink, H. A., et al. (2004). Vision impairment and combined vision and hearing impairment predict cognitive and functional decline in older women. *J. Am. Geriatr. Soc.* 52, 1996–2002. doi: 10.1111/j.1532-5415.2004.52554.x
- Liu, P. L., Cohen, H. J., Fillenbaum, G. G., Burchett, B. M., and Whitson, H. E. (2016). Association of co-existing impairments in cognition and self-rated vision and hearing with health outcomes in older adults. *Gerontol. Geriatr. Med.* 2, 1–9. doi: 10.1177/2333721415623495
- Loprinzi, P. D., and Addoh, O. (2016). Predictive validity of the american college of cardiology/american heart association pooled cohort equations in predicting all-cause and cardiovascular disease-specific mortality in a national prospective cohort study of adults in the United States. *Mayo Clin. Proc.* 91, 763–769. doi: 10.1016/j.mayocp.2016.03.019
- Loprinzi, P. D., Crush, E., and Joyner, C. (2017). Cardiovascular disease biomarkers on cognitive function in older adults: joint effects of cardiovascular disease biomarkers and cognitive function on mortality risk. *Prev. Med.* 94, 27–30. doi: 10.1016/j.ypmed.2016.11.011
- Majer, I. M., Nusselder, W. J., Mackenbach, J. P., Klijs, B., and van Baal, P. H. (2011). Mortality risk associated with disability: a population-based record linkage study. *Am. J. Public Health* 101, e9–e15. doi: 10.2105/AJPH.2011.300361
- McCarty, C. A., Nanjan, M. B., and Taylor, H. R. (2001). Vision impairment predicts 5 year mortality. *Br. J. Ophthalmol.* 85, 322–326. doi: 10.1136/bjo.85.3.322
- McGuire, L. C., Ford, E. S., and Ajani, U. A. (2006). The impact of cognitive functioning on mortality and the development of functional disability in older adults with diabetes: the second longitudinal study on aging. *BMC Geriatr.* 6:8. doi: 10.1186/1471-2318-6-8
- Mitoku, K., Masaki, N., Ogata, Y., and Okamoto, K. (2016). Vision and hearing impairments, cognitive impairment and mortality among long-term care recipients: a population-based cohort study. *BMC Geriatr.* 16:112. doi: 10.1186/s12877-016-0286-2
- Muir, S. W., Gopaul, K., and Montero Odasso, M. M. (2012). The role of cognitive impairment in fall risk among older adults: a systematic review and meta-analysis. *Age Ageing* 41, 299–308. doi: 10.1093/ageing/afs012
- Ng, S. K., Kahawita, S., Andrew, N. H., Henderson, T., Craig, J. E., and Landers, J. (2018). Association of visual impairment and all-cause 10-year mortality among indigenous australian individuals within central australia: the central australian ocular health study. *JAMA Ophthalmol.* 136, 534–537. doi: 10.1001/jamaophthalmol.2017.6787
- NHANES (1999–2000). *Data Documentation, Codebook, and Frequencies: Cognitive Functioning (CFQ): Appendix 1: NHANES Digit Symbol Substitution Exercise (CFQ): Interviewer Instructions.* Available at: [https://www.cdc.gov/Nchs/Nhanes/1999-2000/CFQ.htm#Appendix\\_1:\\_NHANES\\_DIGIT\\_SYMBOL\\_SUBSTITUTION\\_EXERCISE\\_\(CFQ\):\\_Interviewer\\_Instructions](https://www.cdc.gov/Nchs/Nhanes/1999-2000/CFQ.htm#Appendix_1:_NHANES_DIGIT_SYMBOL_SUBSTITUTION_EXERCISE_(CFQ):_Interviewer_Instructions). Accessed Feb 19, 2019.
- NHANES (2001–2002). *Data Documentation, Codebook, and Frequencies: Cognitive Functioning (CFQ): Appendix 1: NHANES Digit Symbol Substitution Exercise (CFQ): Interviewer Instructions.* Available at: [https://www.cdc.gov/Nchs/Nhanes/2001-2002/CFQ\\_B.htm#Appendix\\_1](https://www.cdc.gov/Nchs/Nhanes/2001-2002/CFQ_B.htm#Appendix_1). Accessed Feb 19, 2019.
- Perna, L., Wahl, H. W., Mons, U., Saum, K. U., Hollecek, B., and Brenner, H. (2015). Cognitive impairment, all-cause and cause-specific mortality among non-demented older adults. *Age Ageing* 44, 445–451. doi: 10.1093/ageing/afu188
- Rogers, M. A., and Langa, K. M. (2010). Untreated poor vision: a contributing factor to late-life dementia. *Am. J. Epidemiol.* 171, 728–735. doi: 10.1093/aje/kwp453
- Sachs, G. A., Carter, R., Holtz, L. R., Smith, F., Stump, T. E., Tu, W., et al. (2011). Cognitive impairment: an independent predictor of excess mortality: a cohort study. *Ann. Intern. Med.* 155, 300–308. doi: 10.7326/0003-4819-155-5-201109060-00007
- Tamura, H., Tsukamoto, H., Mukai, S., Kato, T., Minamoto, A., Ohno, Y., et al. (2004). Improvement in cognitive impairment after cataract surgery in elderly patients. *J. Cataract. Refract. Surg.* 30, 598–602. doi: 10.1016/j.jcrs.2003.10.019
- Varma, R., Bressler, N. M., Doan, Q. V., Gleeson, M., Danese, M., Bower, J. K., et al. (2014). Prevalence of and risk factors for diabetic macular edema in the United States. *JAMA Ophthalmol.* 132, 1334–1340. doi: 10.1001/jamaophthalmol.2014.2854
- Varma, R., Vajaranant, T. S., Burkemper, B., Wu, S., Torres, M., Hsu, C., et al. (2016). Visual impairment and blindness in adults in the united states: demographic and geographic variations from 2015 to 2050. *JAMA Ophthalmol.* 134, 802–809. doi: 10.1001/jamaophthalmol.2016.1284
- Wang, J. J., Mitchell, P., Simpson, J. M., Cumming, R. G., and Smith, W. (2001). Visual impairment, age-related cataract, and mortality. *Arch. Ophthalmol.* 119, 1186–1190. doi: 10.1001/archophth.119.8.1186
- Wechsler, D. (2007). Wechsler adult intelligence scale-III (WAIS-III). New York: psychological corporation; 1997. *Am. J. Epidemiol.* 165, 344–350.

- Whitson, H. E., Cousins, S. W., Burchett, B. M., Hybels, C. F., Pieper, C. F., and Cohen, H. J. (2007). The combined effect of visual impairment and cognitive impairment on disability in older people. *J. Am. Geriatr. Soc.* 55, 885–891. doi: 10.1111/j.1532-5415.2007.01093.x
- Yeh, S. C., and Liu, Y. Y. (2003). Influence of social support on cognitive function in the elderly. *BMC Health Serv. Res.* 3:9. doi: 10.1186/1472-6963-3-9
- Zhang, T., Jiang, W., Song, X., and Zhang, D. (2016). The association between visual impairment and the risk of mortality: a meta-analysis of prospective studies. *J. Epidemiol. Commun. Health* 70, 836–842. doi: 10.1136/jech-2016-207331
- Zhu, Z., Wang, L., Young, C. A., Huang, S., Chang, B. H., and He, M. (2016). Cataract-related visual impairment corrected by cataract surgery and 10-year mortality: the liwan eye study. *Invest. Ophthalmol. Vis. Sci.* 57, 2290–2295. doi: 10.1167/iops.15-17673
- Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- Copyright © 2019 Liao, Zhu, Wang, Rong, Young and Peng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.